Entera Bio (ENTX) 10-K 8 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 01, 2022	Jun. 30, 2021
Cover [Abstract]
Entity Public Float			$ 142.1
Entity Registrant Name	Entera Bio Ltd.
Document Type	10-K
Document Period End Date	Dec. 31, 2021
Entity Central Index Key	0001638097
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		28,804,411
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Shell Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	Kiryat Hadassah
Entity Address, Address Line Two	Minrav Building – Fifth Floor
Entity Address, City or Town	Jerusalem
Entity Address, Postal Zip Code	9112002
Entity Address, Country	IL
City Area Code	972
Local Phone Number	2-532-7151
Document Transition Report	false
Entity File Number	001-38556
Entity Tax Identification Number	00-0000000
Trading Symbol	ENTX
Security Exchange Name	NASDAQ
Title of 12(b) Security	Ordinary shares,
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Annual Report	true
Auditor Name	Kesselman & Kesselman
Auditor Location	Tel-Aviv, Israel
Auditor Firm ID	1309

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents		$ 24,892	$ 8,593
Accounts receivable		183	255
Other current assets		254	261
TOTAL CURRENT ASSETS		25,329	9,109
NON-CURRENT ASSETS:
Property and equipment, net		156	192
Operating lease right-of-use assets		239	374
Deferred income taxes		217	0
Funds in respect of employee rights upon retirement		46	47
TOTAL NON-CURRENT ASSETS		658	613
TOTAL ASSETS		25,987	9,722
CURRENT LIABILITIES:
Accounts payable		166	164
Accrued expenses and other payables		2,801	1,330
Current maturities of operating lease		179	189
Contract liabilities		15	158
TOTAL CURRENT LIABILITIES		3,161	1,841
NON-CURRENT LIABILITIES:
Operating lease liabilities		123	243
Liability for employee rights upon retirement		138	128
TOTAL NON-CURRENT LIABILITIES		261	371
TOTAL LIABILITIES		3,422	2,212
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2021 and December 31, 2020, 140,010,000 shares; issued and outstanding: - as of December 31, 2021, and December 31, 2020 28,804,411 and 21,057,922 shares, respectively	[1]
Additional paid-in capital		104,950	77,708
Accumulated other comprehensive income		41	41
Accumulated deficit		(82,426)	(70,239)
TOTAL SHAREHOLDERS' EQUITY		22,565	7,510
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$ 25,987	$ 9,722
[1]	Represents an amount less than one thousand US dollars

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - ₪ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Ordinary share, par value	₪ 0.0000769	₪ 0.0000769
Ordinary shares, authorized	140,010,000	140,010,000
Ordinary shares, issued	28,804,411	21,057,922
Ordinary shares, outstanding	28,804,411	21,057,922

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
REVENUES	$ 571	$ 365
COST OF REVENUES	373	300
GROSS PROFIT	198	65
OPERATING EXPENSES:
Research and development	6,771	6,382
General and administrative	5,690	4,851
Other income	(46)	0
TOTAL OPERATING EXPENSES	12,415	11,233
OPERATING LOSS	12,217	11,168
FINANCIAL EXPENSES, net	29	28
LOSS BEFORE INCOME TAX	12,246	11,196
INCOME TAX (BENEFIT) EXPENSE	(59)	20
NET LOSS	$ 12,187	$ 11,216
LOSS PER SHARE BASIC AND DILUTED	$ 0.47	$ 0.67
WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE	26,133,770	18,417,093

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Ordinary shares [Member]		Additional paid-in capital [Member]	Accumulated other Comprehensive income [Member]	Accumulated deficit [Member]	Total
Balance at Dec. 31, 2019		[1]	$ 72,756	$ 41	$ (59,023)	$ 13,774
BALANCE (in shares) at Dec. 31, 2019	17,864,684
CHANGES DURING THE YEAR ENDED
Net loss	$ 0		0	0	(11,216)	(11,216)
Issuance of ordinary shares and warrants due to a private placement net of issuance costs	$ 0		796	0	0	796
Issuance of ordinary shares and warrants due to a private placement net of issuance costs (in shares)	337,553
Issuance of shares due to the ATM program, net of issuance costs	$ 0		3,187	0	0	3,187
Issuance of shares due to the ATM program, net of issuance costs (in shares)	2,802,731
Exercise of options to ordinary shares	$ 0		68	0	0	$ 68
Exercise of options to ordinary shares (in shares)	31,954					31,954
Share-based compensation	$ 0		901	0	0	$ 901
Vested restricted share units	$ 0		0	0	0	0
Vested restricted share units (in shares)	21,000
BALANCE (in shares) at Dec. 31, 2020	21,057,922
Balance at Dec. 31, 2020		[1]	77,708	41	(70,239)	7,510
CHANGES DURING THE YEAR ENDED
Net loss	0		0	0	(12,187)	(12,187)
Issuance of shares due to the ATM program, net of issuance costs		[1]	21,805	0	0	21,805
Issuance of shares due to the ATM program, net of issuance costs (in shares)	4,386,728
Exercise of options to ordinary shares	$ 0		418	0	0	$ 418
Exercise of options to ordinary shares (in shares)	177,711					177,710
Exercise of warrants to ordinary shares	$ 0		3,158	0	0	$ 3,158
Exercise of warrants to ordinary shares (in shares)	3,175,050
Share-based compensation	$ 0		1,861	0	0	1,861
Vested restricted share units	$ 0		0	0	0	0
Vested restricted share units (in shares)	7,000
BALANCE (in shares) at Dec. 31, 2021	28,804,411
Balance at Dec. 31, 2021		[1]	$ 104,950	$ 41	$ (82,426)	$ 22,565
[1]	Represents an amount less than one thousand US dollars.

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,187)	$ (11,216)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	53	63
Deferred income taxes	(217)	0
Share-based compensation	1,861	901
Finance expenses (income), net	18	46
Changes in operating asset and liabilities:
Decrease in accounts receivable	72	23
Decrease (increase) in other current assets	7	(55)
Increase (decrease) in accounts payable	2	(170)
Increase (decrease) in accrued expenses and other payables	1,471	(40)
Increase (decrease) in contract liabilities	(143)	(109)
Net cash used in operating activities	(9,063)	(10,557)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(17)	(53)
Net cash used in investing activities	(17)	(53)
Cash flows from financing activities:
Proceeds from issuance of shares and warrants, net of issuance costs	0	796
Proceeds from issuance of shares through ATM programs, net of issuance costs	21,805	3,187
Exercise of options and warrants into shares	3,576	68
Net cash provided by financing activities	25,381	4,051
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	16,301	(6,559)
CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE YEAR	8,663	15,222
CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE YEAR	24,964	8,663
Reconciliation in amounts on consolidated balance sheets:
Cash and cash equivalents	24,892	8,593
Restricted deposits included in other current assets	72	70
Total cash and cash equivalents and restricted cash	24,964	8,663
SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:
Income taxes paid in cash during the year	2	89
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Cashless exercise of warrants
Operating lease right of use assets obtained in exchange for new operating lease liabilities	$ 31	$ 258

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 - GENERAL a. Entera as incorporated on September 30, 2009 and commenced operation on June 1, 2010. On January 8, 2018 the Company incorporated Entera Bio Inc., a wholly owned subsidiary incorporated in Delaware USA. The Company is a leader in the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism, are based on its proprietary technology platform and are both in Phase 2 clinical development. The Company also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has completed one such agreement with Amgen Inc . b. The Company's securities have been listed for trading on the Nasdaq Capital Market since the Company’s initial public offering in July 2018, where a total of 1,400,000 ordinary shares and 1,400,000 warrants (the “IPO warrants”) to purchase up to 700,000 ordinary shares were issued in consideration of net proceeds of $9.6 million, after deducting offering expenses . The public offering price was $8.00 per unit c. On . The . d. Since .

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Basis of presentation of the financial statements The . b. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. c. Functional currency 1) Functional and presentation currency Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The U.S. dollar is the currency of the primary economic environment in which the operations of the Company is conducted. The consolidated financial statements are presented in U.S. dollars. 2) Transactions and balances Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non- U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions – exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) – historical exchange rates. Currency transaction gains and losses are presented in financial income (expenses), as appropriate . The functional currency of the subsidiary is the U.S. dollar. d. Principles of consolidation The consolidated financial statements include the accounts of the Company and Entera Bio Inc. All inter-company transactions and balances have been eliminated in consolidation. e. Cash and cash equivalents The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. f. Restricted Restricted cash deposited in an interest-bearing saving account which is used as a security for the Company's office rent, and credit card. g. Fair value measurement The Level Level Level h. Employee severance benefits Under In With The The i. Leases On ROU The . Sublease income is recognized on a straight-line basis over the expected lease term and is included in other income in our consolidated statements of operations . j. Property and equipment 1) Property and equipment are stated at cost, net of accumulated depreciation and amortization. 2) The : Years Computer equipment 3-5 Office furniture 10 Laboratory equipment 7-10 Leasehold improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life of the improvements. k. Impairment of long-lived assets The . l. Share-based compensation The . The . The . The . The . m. Research and development expenses Research . Grants . n. Revenue recognition The Company recognized revenue from the Amgen Agreement which was signed in December 2018 according to ASC 606, "Revenues from Contracts with Customers”. Prior to the signing of the Amgen Agreement in 2018, the Company did not have revenue transactions. ASC 606 Revenue from Contracts with Customer introduces a five-step model for recognizing revenue from contracts with customers, as follows: 1. Identify the contract with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfies a performance obligation. According to ASC 606, a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Options granted to the customer that do not provide a material right to the customer that it would not receive without entering into the contract do not give rise to performance obligations. On December 10, 2018, the Company entered into the Amgen Agreement in inflammatory disease and other serious illnesses. As part of the agreement, the Company received non-refundable and non-creditable initial access payment of $725 from Amgen in January 2019. The Company identified two performance obligations in the agreement: 1) License to use the Company's proprietary drug delivery platform and 2) pre-clinical research and development services (“pre-clinical R&D services”). The preclinical R&D services include discovery, research and design preclinical activities relating to the programs selected by Amgen. The . Revenues attributed to the preclinical R&Ds services are recognized during the period of the pre-clinical R&D services, over time according to the input model method on a cost-to-cost basis, since the customer benefits from the research and development services as the entity performs the service. The Company evaluated the standalone selling price of the pre-clinical R&D services at $225 and the right to use the intellectual property at $500. The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements) . Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent upon the occurrence of future events of development and commercial progress, are a form of variable consideration. When assessing the portion, if any, of such milestones-related consideration to be included in the transaction price, the Company first assesses the most likely outcome for each milestone and excludes the consideration related to milestones of which the occurrence is not considered the most likely outcome. The Company then evaluates if any of the variable consideration determined in the first step is constrained. Variable consideration is included in the transaction price if, in the Company’s judgment, it is highly probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. A s of December 31, 2021, the Company did not recognize any revenues from any potential milestone payments. An entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only when (or as) the later of the following events occurs: a) The subsequent sale or usage occurs; and b) The performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As . o. Income taxes 1) Deferred taxes Deferred . 2) Uncertainty in income taxes The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being realized upon ultimate settlement. p. Loss per share Basic . Diluted 6,517,102 shares and 7,218,966 q. Legal and other contingencies Certain . Management . Legal costs incurred in connection with loss contingencies are expensed as incurred . r. Derivatives Freestanding . If . s. Newly issued and recently adopted accounting pronouncements: Recently issued accounting pronouncements, not yet adopted 1) In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832)”, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. 2) In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments to this guidance are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. 3) In June 2016, the FASB issued ASU 2016-13 “Financial Instruments—Credit Losses—Measurement of Credit Losses on Financial Instruments.” This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal year beginning on January 1, 2023, including interim periods within that year. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.

COVID-19

COVID-19	12 Months Ended
	Dec. 31, 2021
Unusual or Infrequent Items, or Both [Abstract]
COVID-19	NOTE 3 - COVID-19 In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic. The COVID-19 pandemic is having widespread, rapidly evolving, and unpredictable impacts on global society, economies, financial markets, and business practices. During 2021, there was a broad distribution of several vaccinations and medicines to overcome the pandemic. The Company has shifted its operations to co-exist along the pandemic with encouragement of vaccinations to all of its employees. Though the Company sees great progress to overcome the COVID-19 pandemic, still the COVID-19 pandemic may continue to impact the Company’s business operations, with outbursts of new variants of the COVID-19 from time to time, and there is uncertainty in the nature and degree of its continued effects over time.

OPERATING LEASES

OPERATING LEASES	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
OPERATING LEASES	NOTE 4 - OPERATING LEASES 1) The Company leases office and research and development space under several agreements. The annual lease consideration is a total of $ 192 and is linked to the Israeli CPI. The lease agreement will expire on June 30, 2023. As of December 31, 2021, the Company provided bank guarantees of approximately $42, in the aggregate, to secure the fulfillment of its obligations under the lease agreements. 2) The Company has entered into operating lease agreements for vehicles used by its employees. The lease periods are generally for three years and the payments are linked to the Israeli CPI. To secure the terms of the lease agreements, the Company has made certain prepayments to the leasing company, representing approximately three months of lease payments. The annual lease consideration is a total of $ 36 The lease cost was as follows: Year ended December 31, 2021 Year ended December 31, 2020 Operating lease cost 216 180 Supplemental cash flow information related to leases was as follows: Year ended December 31, 2021 Year ended December 31, 2020 Operating cash flows from operating leases 216 180 Supplemental balance sheet information related to operating leases was as follows: December 31, 2021 December 31, 2020 Operating Leases Operating lease right-of-use assets 239 374 Current lease liabilities 179 189 Non-current lease liabilities 123 243 Total lease liabilities 302 432 Weighted-average remaining lease term (in years) 1.53 2.53 Weighted-average discount rate 16 % 16 % As of December 31, 2021, the maturity of lease liabilities under our non-cancelable operating leases were as follows: 2022 224 2023 117 Total future minimum lease payments 341 Less: interest (39 ) Present value of operating lease liabilities 302

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 5 - COMMITMENTS AND CONTINGENCIES a. Commitment to pay royalties to the government of Israel The . Under the terms of the Company’s funding from the IIA, royalties are payable on sales of products developed from projects so funded of 3% during the first three years, from commencement of revenues, 4% during the subsequent three years and 5% commencing the seventh year up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest based on LIBOR. The amount that must be repaid may be increased to three times the amount of the grant received, and the rate of royalties may be accelerated, if manufacturing of the products developed with the grant money is transferred outside of the State of Israel. As $460. Following 5.38% of $79 to the IIA. b. On June 1, 2010 D.N.A. Biomedical Solutions Ltd. ("D.N.A.") and Oramed Ltd., ("Oramed") entered into a joint venture agreement, (the "Joint Venture Agreement") for the establishment of Entera Bio Ltd. According to the Joint Venture Agreement each of D.N.A. and Oramed acquired 50% of the Company's ordinary shares. D.N.A invested $600 in the Company, and Oramed and the Company entered into a Patent License Agreement pursuant to which Oramed licensed to the Company certain of Oramed's patent (the “IPR&D”). On February 22, 2011, Oramed and the Company entered into a patent transfer agreement, (the "Patent Transfer Agreement"), that superseded the Patent License Agreement, whereby Oramed assigned to the Company all of its rights, title and interest to its patent that Oramed licensed to the Company in 2010, under certain conditions. Under this agreement, the Company is obligated to pay Oramed royalties equal to 3% of its net revenues (as defined in the Patent Transfer Agreement).

SHARE CAPITAL

SHARE CAPITAL	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
SHARE CAPITAL	NOTE 6 - SHARE CAPITAL 1) Rights of the Company’s ordinary shares Each ordinary share is entitled to one vote. The holder of the ordinary shares is also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. The right to receive upon liquidation of the Company a sum equal to the nominal value of the share, and if a surplus remains, to receive such surplus, subject to the rights conferred on any class of shares which may be issued in the future. Since its inception, the Company has not declared any dividends. 2) Changes in share capital: a. IPO warrants As described in note 1b, in July 2018 the Company issued 1,400,000 IPO warrants to purchase 700,000 ordinary shares of the Company, these warrants have been listed for trading on the Nasdaq Capital Market and trading began on August 12, 2018. The IPO warrants are exercisable immediately at an initial exercise price of $8.40 per ordinary share for a period of five years, unless earlier repurchased by the Company under "Fundamental Transactions” as described in the warrant agreement or early expired as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of each warrant are subject to standard adjustments. In addition, the exercise price is subject to reduction if, within two years of the date of original issuance of the warrants which ended in July 2020, the Company sells or grants any warrant or option (except in certain circumstances as described in the warrant agreement) at an effective price per share less than $8.00 per share (as adjusted in proportion with any adjustments made from time to time), which reduction will be based on a weighted average, as described in the agreement. As described in note 6(2)b below, the Company completed financing round in a price per share lower than the $8.00, therefore, the adjusted exercise price is $5.85. At the IPO completion date, both of the instruments (warrants and shares) were classified as equity instruments as the warrants are considered indexed to the entity's own stock based on the provision of ASC 815. As of the December 31, 2021 there are 1,395,500 traded warrants to purchase 697,750 ordinary shares of the Company with an exercise price of $5.85. b. On December 11, 2019 and December 18, 2019 (“the first and second closing”), the Company entered into subscription agreements with a selected group of accredited investors, including certain board members and their affiliates for the private placement of 5,710,153 ordinary shares for aggregate subscription proceeds to the Company of $13.5 million at a price of $2.37 per share. In addition, the Company granted 2,855,095 warrants, exercisable over a three-years period from the date of issuance, to purchase 2,855,095 ordinary shares at a per share exercise price of $2.96. In addition, the exercise price is subject to reduction if, within one years of the date of original issuance of the warrants which ended in December 2020 the Company will issue ordinary shares at an effective price per share less than $2.96. In addition, on December 13, 2019, D.N.A Biomedical Solutions Ltd. (“DNA”), an existing shareholder of the Company, subscribed to the Private Placement (the “DNA Private Placement”) to purchase 337,553 ordinary shares for aggregate consideration of $800. In connection with the transaction, the Company granted DNA warrants, exercisable over a three-year period from the date of issuance, to purchase 168,776 ordinary shares at a per share exercise price of $2.96. This investment was approved by the shareholders of the Company on February 18, 2020. The 168,776 warrants issued in connection with the DNA Private Placement together with the 2,855,095 warrants issued in connection with the Private Placement are the “Investors Warrants” In connection therewith, the Company entered into Placement Agency agreement with GP Numenkari Inc., a broker-dealer (“the Broker”). Based on the agreement, the Broker was entitled to the following consideration: 1. A cash fee equal to 10% of the total proceeds paid by subscribers invested through the Broker. 2. Three-years warrants to purchase ordinary shares in the amount equal to 10% of the number of shares issued to subscribers invested through the Broker at a per share exercise price of $2.37 (“Broker Warrants Type 1”). 3. Three-years warrants to purchase ordinary share in the amount equal to 5% of number of shares issued to subscribers invested through the Broker at a per share exercise price of $2.96 (“Broker Warrants Type 2”), together with the Broker Warrants Type 1 (the “Broker Warrants”). Following the first and second closing of the offering, the Company issued 184,515 Broker Warrants type 1 and 92,257 Broker Warrants type 2 at per share exercise price of $2.37 to $2.96, respectively The Company had transaction costs of approximately $1.2 million, out of which $205 are Stock-Based Compensation due to issuance of the Broker Warrants. At the transaction date, both of the instruments (shares and warrants) were classified as equity instruments as the warrants are considered indexed to the entity's own stock based on the provision of ASC 815. During 2020, upon issuance of shares through the Company’s At-the-market equity program at a price per share lower than the exercise price, the exercise price adjusted to $1.05. See note 6(2)e. On April 21, 2021, upon satisfaction of the sale price condition pursuant to the subscription agreement signed in December 2019, the Company’s Board of Directors decided to accelerate the termination date of the Investors and Broker warrants issued in December 2019 and February 2020. In accordance with the terms of the agreement, as of the notice date and until June 23, 2021 (the “Early Termination Exercise Period”), the holders may exercise their warrants and following such Early Termination Exercise Period, these warrants shall be deemed terminated. Through June 23, 2021, all warrants holders, including the company's Chairman of the board and DNA, exercised 3,300,645 warrants into 3,172,800 ordinary shares through cash or cashless mechanism. The total consideration from the exercise of these warrants was $3,145 at an exercise price of $1.05. As of December 31, 2021, all Investors and Broker warrants were exercised. c. On June 13, 2020, 687,960 warrants to purchase 687,960 ordinary shares for a purchase price of $6.99 per share in accordance with the Series B preferred share purchase agreement signed in 2016 and its following amendments expired. d. In July 2020, 340,210 warrants to purchase 340,210 ordinary shares for a purchase price of $3.69 per share in accordance with the Series A preferred share purchase agreement expired. e. On July 4, 2020, the Company established a primary registration statement under form F-3 and at-the-market equity program (the " 2020 ATM Program") that allows the Company to issue up to $13.9 million of ordinary shares, at the Company's discretion. Distributions of the ordinary shares through 2020 ATM Program were made pursuant to the terms of an equity distribution agreement dated July 13, 2020 among the Company and Canaccord Genuity LLC (the "Agent"). In February and March 2021, the Company issued additional 2,546,265 ordinary shares for net proceeds of $9.9 million at a weighted average price of $3.99 per ordinary share through 2020 ATM Program. f. On May 7, 2021, the Company entered into a new At-the-market equity program (the "2021 ATM Program") that allows the Company to issue up to additional 5 million ordinary shares, at the Company's discretion. Distributions of the ordinary shares through the 2021 ATM Program were made pursuant to the terms of an equity distribution agreement dated May 7, 2021 among the Company and B. Riley Securities, Inc. In June and July 2021, the Company issued 1,840,463 ordinary shares for net proceeds of $12.1 million at a weighted average price of $6.74 per ordinary share through the Company’s 2021 ATM Program. g. During the twelve months ended December 31, 2021, several employees and service providers exercised 177,711 options into 177,711 ordinary shares of the Company for a total consideration of $418 at a weighted average price of $2.54 per ordinary share.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 7 - SHARE-BASED COMPENSATION 1) Share-based compensation plan On March 17, 2013, the Company's Board of Directors approved a Share Incentive Plan (the “2013 Plan”). Under the 2013 Plan, the Company shall reserve sufficient number of ordinary shares, NIS 0.000769 par value, of the Company for allocation of stock options, restricted share units, restricted share awards and performance-based awards (the "Option"), to employees and non-employees. Each Option is exercisable for one ordinary share. Any option granted under the 2013 Plan that is not exercised within six years from the date upon which it becomes exercisable will expire. On July 2, 2018, the Company's board of directors and shareholders of the Company approved a new Share Incentive Plan (the “2018 Plan”) and reserved 1,371,398 ordinary shares of the Company for allocation of stock options, restricted share units, restricted share awards and performance-based awards (the "Option"), to employees and non-employees for issuance under the 2018 Plan. Each Option is exercisable for one ordinary share NIS 0.0000769 par value. Any option granted under 2018 Plan that is not exercised within 10 years from the date upon which it becomes exercisable will expire. The options granted to employees are subject to the terms stipulated by section 102(b)(2) of the Israeli Income Tax Ordinance (the “Ordinance”). According to these provisions, the Company will not be allowed to claim as an expense for tax purposes the amounts credited to the employees as a capital gain benefit in respect of the options granted. Options granted to related parties or non-employees of the Company are governed by Section 3(i) of the Ordinance or Non-Qualified Share Options ("NSO"). The Company will be allowed to claim as an expense for tax purposes in the year in which the related parties or non-employees exercised the options into shares. As of December 31, 2021, 289,638 ordinary shares remain available for future grants under the Plan. On January 1, 2022 the Company’s Board of Directors approved an increase of 1,440,220 ordinary shares that may be issued under the Company’s Plan. 2) share-based compensation grants to employees and directors: a) On March 16, 2020, the Company’s Board of Directors approved the following option grants, with an exercise price of $2.14 per share: 1. 250,000 options to purchase ordinary shares were granted to certain executive officers. 2. 201,600 options to purchase ordinary shares were granted to certain employees. 3. 7,500 options to purchase ordinary shares was granted to a service provider. The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair value of the options at the date of grant was $590. b) On April 20, 2020 options to purchase 31,502 ordinary shares granted to the former CEO with an exercise price of $1.98 per share. The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair value of the options at the date of grant was $37. Effective September 7, 2020, due to termination of the employment agreement with the former CEO, these options are forfeited and recognized as a reverse of expense under the General and Administrative line. c) In April 2020, the Company entered into an investor relations services agreement. Under the terms of the agreement, the Company agreed to pay a monthly fee of $5 and to issue the consultant 28,000 Restricted Share Units (“RSU”), of which the first 7,000 shares vested on the signing date and the remaining 21,000 shares will vest in three equal installments until January 8, 2021. As of December 31, 2020, 21,000 shares were fully vested. The fair value of the RSU was $53 using the fair value of the shares at the grant date. d) In November 2020, the Company entered into an amendment to business development services agreement with the business development consultant. Under the terms of the agreement, the Company agreed to pay a monthly fee of $5 and to issue the consultant 79,760 options with an exercise price of $1.06 per share. The options vests over 6 months in six equal installments from October 1, 2020. The fair value of the options at the date of grant was $35. e) On January 4, 2021 options to purchase 1,314,218 ordinary shares were granted to the Chief Executive Officer of the Company, with an exercise price of $1.24. The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The grant was subject to the approval by the shareholders of the Company, which approved the grant in March 2021. The fair value of the options at the date of grant was $1,320. f) On April 7, 2021, the Company’s Board of Directors approved the following option grants: i. Options grants to purchase 213,000 ordinary shares to certain employees and 70,000 options granted to service providers, with an exercise price of $3.61 per share. The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the options at the date of grant was $646. ii. Options grant to purchase 33,368 ordinary shares to a non-executive director of the Company, with an exercise price of $3.61. The options will vest over 3 years in twelve equal quarterly instalments starting on the vesting commencement date. These options were subject to the approval of the shareholders of the Company, which was approved on October 4, 2021. The fair value of the options at the shareholders' approval date was $104. g) On April 21, 2021, options to purchase 345,000 ordinary shares were granted to several executive officers of the Company, with an exercise price of $3.15. The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. These options were subject to the approval of the shareholders of the Company, which was approved on October 4, 2021. The fair value of the options at the shareholders' approval date was $1,140. h) On August 23. 2021, the Company’s Board of Directors approved the following option grants which were approved by the shareholders of the Company on October 4, 2021. i. Grants of options to purchase ordinary shares with a total fair value 0f $195 for each of the seven non-executive board member on January 1, 2022. The options will vest over 3 years in twelve equal quarterly instalments starting on January 1, 2022 the vesting commencement date. On January 1, 2022, which is considered the awards grant date, the Company granted 752,899 ordinary shares to non-executive directors with an exercise price of $2.815 per share. ii. Grants of options to purchase ordinary shares with a total fair value 0f $65 for each of the seven non-executive board member on January 1, 2022. The options will vest over 1 year in four equal quarterly instalments starting on January 1, 2022 the vesting commencement date. On January 1, 2022, which is considered the awards grant date, the Company granted 250,964 ordinary shares to non-executive directors with an exercise price of $2.815 per share. The fair value of each option granted is estimated at the date of grant using the Black-Scholes option-pricing model, with the following weighted average assumptions: 2021 2020 Exercise price $ 1.24-$3.61 $ 1.06-$2.14 Dividend yield - - Expected volatility 68%-71 % 66.35%-71 % Risk-free interest rate 1.11%-0.94 % 0.16%-0.58 % Expected life - in years 6.1-5.8 2.75-6.1 2021 2020 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of year 2,570,109 $ 4.85 2,847,600 $ 4.74 Granted 1,975,586 1.95 570,362 $ 1.98 Exercised (177,710 ) 2.37 (31,954 ) 2.11 Forfeited (16,660 ) 2.37 (589,793 ) 2.7 Expired (34,466 ) 4.00 (226,106 ) 2.68 Outstanding at end of year 4,316,859 $ 3.63 2,570,109 $ 4.85 Exercisable at end of year 2,068,067 $ 5.39 1,791,687 $ 5.49 The following tables summarizes information concerning outstanding and exercisable options as of December 31, 2021, in terms of ordinary shares: December 31, 2021 Options outstanding Options exercisable Number of Weighted Number of Weighted options Average options Average Exercise outstanding Remaining exercisable Remaining prices per at end of Contractual at end of contractual share (USD) year Life year Life - 4,680 0.78 4,680 0.78 1.06 14,760 3.85 14,760 3.85 1.24 1,314,218 9.02 - - 2.14 422,300 8.26 184,756 8.26 2.53 33,638 7.89 28,031 7.89 3.15 345,000 9.30 - - 3.61 316,368 9.27 5,561 9.27 3.68 185,640 0.32 185,640 0.32 3.97 287,565 7.05 251,949 7.05 6.31 1,245,400 4.08 1,245,400 4.08 7.54 147,290 1.26 147,290 1.26 4,316,859 2,068,067 The aggregate intrinsic value of the total of the outstanding and exercisable options as of December 31, 2021, is $2,378 and $146, respectively. The following table illustrates the effect of share-based compensation on the statements of operations: 2021 2020 Cost of revenues 102 51 Research and development expenses 661 514 General and administrative 1,098 336 1,861 901

INCOME TAX

INCOME TAX	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 8 - INCOME TAX A. Corporate tax rate 1) Ordinary taxable income in Israel is subject to a corporate tax rate of 23%. 2) 29%. B. Losses for tax purposes carried forward to future years The balance of carryforward losses as of December 31, 2021 and 2020 are approximately $56.1 million and $44.2 million, respectively. Under Israeli tax law, tax loss carry forward have no expiration date. C. Tax assessments The Company and its subsidiary have tax assessments that are considered to be final through tax year 2016. D. Loss (income) before income taxes is composed of the following Year ended December 31 2021 2020 Entera Bio Ltd 12,362 11,283 Entera Bio Inc (116 ) (87 ) Total loss before taxes 12,246 11,196 E. Tax expenses: Year ended December 31 2021 2020 Current: Subsidiary 158 20 Total current income tax 158 20 Deferred: Subsidiary (217 ) - Total tax on income (59 ) 20 F. Deferred income taxes December 31, 2021 2020 Deferred tax assets: Net operating loss carry forward 12,895 10,176 Research and development 1,319 1,316 Share-based compensation 876 688 Other 152 240 Net deferred tax assets before valuation allowance 15,242 12,420 valuation allowance (15,025 ) (12,420 ) Net deferred tax assets 217 - Realization of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporary differences and carry forward losses are expected to be available to reduce taxable income. G. Rollforward of valuation allowance: Balance at January 1, 2020 9,718 Additions 2,702 Balance at January 1, 2021 12,420 Additions 2,605 Balance at December 31, 2021 15,025 H. Reconciliation of theoretical tax expenses to actual expenses The primary difference between the statutory tax rate of the Company and the effective rate results virtually from the changes in valuation allowance in respect of carry forward tax losses and research and development expenses due to the uncertainty of the realization of such tax benefits. I. Uncertain tax positions As of December 31, 2021 and 2020, the Company does not have a provision for uncertain tax positions.

SUPPLEMENTARY FINANCIAL STATEME

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	12 Months Ended
	Dec. 31, 2021
Supplementary Financial Statement Information [Abstract]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	NOTE 9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION: Balance sheets: December 31, 2021 2020 U.S. dollars in thousands b. Accounts payable - other: Employees and employees related 147 144 Income tax 134 - Provision for vacation 308 263 Accrued expenses 2,212 923 2,801 1,330

REVENUE FROM COLLABORATION AND

REVENUE FROM COLLABORATION AND LICENSE AGREEMENT	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
REVENUE FROM COLLABORATION AND LICENSE AGREEMENT	NOTE 10 - REVENUE FROM COLLABORATION AND LICENSE AGREEMENT On December 10, 2018, the Company entered into a research collaboration and license agreement (the “Amgen Agreement”) with Amgen Inc. (“Amgen”) in inflammatory disease and other serious illnesses. Pursuant to the Amgen Agreement, the Company and Amgen will use the Company’s proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has options to select up to two additional programs to include in the collaboration. Amgen is responsible for the clinical development, regulatory approval, manufacturing and worldwide commercialization of the programs. The Company granted Amgen an exclusive, worldwide, sublicensable license under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and commercialize the applicable products. The Company will retain all intellectual property rights to its drug delivery technology, and Amgen will retain all rights to its large molecules and any subsequent improvements, and ownership of certain intellectual property developed through the performance of the collaboration is to be determined by U.S. patent law. Pursuant to the terms of the Amgen Agreement, Amgen is required to make aggregate payments of up to $270 million upon achievement of various clinical and commercial milestones or its exercise of options to select additional two programs to include in the collaboration, as well as tiered royalty payments ranging from the low to mid-single digits based on the level of Amgen’s net sales of the applicable products. Amgen is required to pay for the initial program $450 for the second year of preclinical R&D services to be provided by the Company and must reimburse the Company for further expenses as shall be agreed between the parties. Preclinical R&D services includes time spent by the Company's employees performing the Company's activities under the work plan of collaboration program. Amgen’s obligation to pay royalties with respect to a product in a particular country commences upon the first commercial sale of such product in such country and expires on a country-by-country and product-by-product basis on the later of (a) the date on which the sale of the product is no longer covered by a valid claim of a patent licensed to Amgen under the Amgen Agreement, and (b) the tenth anniversary of the first commercial sale of such product in such country. The term of the Amgen Agreement commenced on December 10, 2018, and unless earlier terminated, shall continue in full force and effect, on a product-by-product basis, until expiration of the last-to-expire royalty term with respect to such product. In January 2019, as required by the Amgen Agreement, Amgen paid the Company a non-refundable and non-creditable initial technology access fee of $725. The Company evaluated the selling price of the preclinical R&D services at $225 and the right to use the intellectual property (“License fees”) at $500. In December 2018, the Company recognized $500 in revenues for the right to use the intellectual property. During the second quarter of 2021, the Company extended the agreement, pursuant to the terms, Amgen is required to pay for the third year of preclinical R&D services to be provided by the Company for a total consideration of $450. Revenues attributed to the preclinical R&D services are recognized during the period of the pre-clinical R&D services according to the input model method on a cost-to-cost basis. During 2021 the Company received the second installment for the second year and the first installment for the third year for the pre-clinical R&D services in the amount of $450. In 2021 and 2020, the Company recorded revenues of $502 and $365 related to services provided under the Amgen Agreement. In addition, as of December 31, 2021 and 2020 the Company recorded a contract liability of $15 and $158, respectively.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of presentation of the financial statements	a. Basis of presentation of the financial statements The .
Use of estimates in the preparation of financial statements	b. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.
Functional currency	c. Functional currency 1) Functional and presentation currency Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The U.S. dollar is the currency of the primary economic environment in which the operations of the Company is conducted. The consolidated financial statements are presented in U.S. dollars. 2) Transactions and balances Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non- U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions – exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) – historical exchange rates. Currency transaction gains and losses are presented in financial income (expenses), as appropriate . The functional currency of the subsidiary is the U.S. dollar.
Principles of consolidation	d. Principles of consolidation The consolidated financial statements include the accounts of the Company and Entera Bio Inc. All inter-company transactions and balances have been eliminated in consolidation.
Cash and cash equivalents	e. Cash and cash equivalents The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.
Restricted	f. Restricted Restricted cash deposited in an interest-bearing saving account which is used as a security for the Company's office rent, and credit card.
Fair value measurement	g. Fair value measurement The Level Level Level
Employee severance benefits	h. Employee severance benefits Under In With The The
Leases	i. Leases On ROU The . Sublease income is recognized on a straight-line basis over the expected lease term and is included in other income in our consolidated statements of operations .
Property and equipment	j. Property and equipment 1) Property and equipment are stated at cost, net of accumulated depreciation and amortization. 2) The : Years Computer equipment 3-5 Office furniture 10 Laboratory equipment 7-10 Leasehold improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life of the improvements.
Impairment of long-lived assets	k. Impairment of long-lived assets The .
Share-based compensation	l. Share-based compensation The . The . The . The . The .
Research and development expenses	m. Research and development expenses Research . Grants .
Revenue recognition	n. Revenue recognition The Company recognized revenue from the Amgen Agreement which was signed in December 2018 according to ASC 606, "Revenues from Contracts with Customers”. Prior to the signing of the Amgen Agreement in 2018, the Company did not have revenue transactions. ASC 606 Revenue from Contracts with Customer introduces a five-step model for recognizing revenue from contracts with customers, as follows: 1. Identify the contract with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfies a performance obligation. According to ASC 606, a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Options granted to the customer that do not provide a material right to the customer that it would not receive without entering into the contract do not give rise to performance obligations. On December 10, 2018, the Company entered into the Amgen Agreement in inflammatory disease and other serious illnesses. As part of the agreement, the Company received non-refundable and non-creditable initial access payment of $725 from Amgen in January 2019. The Company identified two performance obligations in the agreement: 1) License to use the Company's proprietary drug delivery platform and 2) pre-clinical research and development services (“pre-clinical R&D services”). The preclinical R&D services include discovery, research and design preclinical activities relating to the programs selected by Amgen. The . Revenues attributed to the preclinical R&Ds services are recognized during the period of the pre-clinical R&D services, over time according to the input model method on a cost-to-cost basis, since the customer benefits from the research and development services as the entity performs the service. The Company evaluated the standalone selling price of the pre-clinical R&D services at $225 and the right to use the intellectual property at $500. The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements) . Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent upon the occurrence of future events of development and commercial progress, are a form of variable consideration. When assessing the portion, if any, of such milestones-related consideration to be included in the transaction price, the Company first assesses the most likely outcome for each milestone and excludes the consideration related to milestones of which the occurrence is not considered the most likely outcome. The Company then evaluates if any of the variable consideration determined in the first step is constrained. Variable consideration is included in the transaction price if, in the Company’s judgment, it is highly probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. A s of December 31, 2021, the Company did not recognize any revenues from any potential milestone payments. An entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only when (or as) the later of the following events occurs: a) The subsequent sale or usage occurs; and b) The performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As .
Income taxes	o. Income taxes 1) Deferred taxes Deferred . 2) Uncertainty in income taxes The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being realized upon ultimate settlement.
Loss per share	p. Loss per share Basic . Diluted 6,517,102 shares and 7,218,966
Legal and other contingencies	q. Legal and other contingencies Certain . Management . Legal costs incurred in connection with loss contingencies are expensed as incurred .
Derivatives	r. Derivatives Freestanding . If .
Newly issued and recently adopted accounting pronouncements	s. Newly issued and recently adopted accounting pronouncements: Recently issued accounting pronouncements, not yet adopted 1) In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832)”, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. 2) In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments to this guidance are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. 3) In June 2016, the FASB issued ASU 2016-13 “Financial Instruments—Credit Losses—Measurement of Credit Losses on Financial Instruments.” This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal year beginning on January 1, 2023, including interim periods within that year. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of estimated useful life	Years Computer equipment 3-5 Office furniture 10 Laboratory equipment 7-10

OPERATING LEASES (Tables)

OPERATING LEASES (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of lease cost	Year ended December 31, 2021 Year ended December 31, 2020 Operating lease cost 216 180
Schedule of operating lease cashflow information	Year ended December 31, 2021 Year ended December 31, 2020 Operating cash flows from operating leases 216 180
Schedule of operating lease liability and operating lease right-of-use asset	December 31, 2021 December 31, 2020 Operating Leases Operating lease right-of-use assets 239 374 Current lease liabilities 179 189 Non-current lease liabilities 123 243 Total lease liabilities 302 432 Weighted-average remaining lease term (in years) 1.53 2.53 Weighted-average discount rate 16 % 16 %
Schedule of maturities of undiscounted lease liabilities	2022 224 2023 117 Total future minimum lease payments 341 Less: interest (39 ) Present value of operating lease liabilities 302

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of fair value assumptions of option granted using Black-Scholes option-pricing model	2021 2020 Exercise price $ 1.24-$3.61 $ 1.06-$2.14 Dividend yield - - Expected volatility 68%-71 % 66.35%-71 % Risk-free interest rate 1.11%-0.94 % 0.16%-0.58 % Expected life - in years 6.1-5.8 2.75-6.1
Schedule of option activity	2021 2020 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of year 2,570,109 $ 4.85 2,847,600 $ 4.74 Granted 1,975,586 1.95 570,362 $ 1.98 Exercised (177,710 ) 2.37 (31,954 ) 2.11 Forfeited (16,660 ) 2.37 (589,793 ) 2.7 Expired (34,466 ) 4.00 (226,106 ) 2.68 Outstanding at end of year 4,316,859 $ 3.63 2,570,109 $ 4.85 Exercisable at end of year 2,068,067 $ 5.39 1,791,687 $ 5.49
Schedule of outstanding and exercisable options of ordinary shares	December 31, 2021 Options outstanding Options exercisable Number of Weighted Number of Weighted options Average options Average Exercise outstanding Remaining exercisable Remaining prices per at end of Contractual at end of contractual share (USD) year Life year Life - 4,680 0.78 4,680 0.78 1.06 14,760 3.85 14,760 3.85 1.24 1,314,218 9.02 - - 2.14 422,300 8.26 184,756 8.26 2.53 33,638 7.89 28,031 7.89 3.15 345,000 9.30 - - 3.61 316,368 9.27 5,561 9.27 3.68 185,640 0.32 185,640 0.32 3.97 287,565 7.05 251,949 7.05 6.31 1,245,400 4.08 1,245,400 4.08 7.54 147,290 1.26 147,290 1.26 4,316,859 2,068,067 The aggregate intrinsic value of the total of the outstanding and exercisable options as of December 31, 2021, is $2,378 and $146, respectively.
Schedule of of share-based compensation on statements of operations	2021 2020 Cost of revenues 102 51 Research and development expenses 661 514 General and administrative 1,098 336 1,861 901

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of loss (income) before income taxes	Year ended December 31 2021 2020 Entera Bio Ltd 12,362 11,283 Entera Bio Inc (116 ) (87 ) Total loss before taxes 12,246 11,196
Schedule of tax expenses	Year ended December 31 2021 2020 Current: Subsidiary 158 20 Total current income tax 158 20 Deferred: Subsidiary (217 ) - Total tax on income (59 ) 20
Schedule of deferred income taxes	December 31, 2021 2020 Deferred tax assets: Net operating loss carry forward 12,895 10,176 Research and development 1,319 1,316 Share-based compensation 876 688 Other 152 240 Net deferred tax assets before valuation allowance 15,242 12,420 valuation allowance (15,025 ) (12,420 ) Net deferred tax assets 217 -
Schedule of rollforward of valuation allowance	Balance at January 1, 2020 9,718 Additions 2,702 Balance at January 1, 2021 12,420 Additions 2,605 Balance at December 31, 2021 15,025

SUPPLEMENTARY FINANCIAL STATE_2

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2021
Supplementary Financial Statement Information [Abstract]
Schedule of accounts payable - other	December 31, 2021 2020 U.S. dollars in thousands b. Accounts payable - other: Employees and employees related 147 144 Income tax 134 - Provision for vacation 308 263 Accrued expenses 2,212 923 2,801 1,330

GENERAL (Detail Textuals)

GENERAL (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021
General [Line Items]
Number of warrants issued	1,395,500
Number of ordinary shares will be purchased by exercising warrants	697,750
Accumulated deficit	$ (82,426)	$ (70,239)
IPO [Member] | Ordinary shares [Member]
General [Line Items]
Number of shares issued	1,400,000
Number of ordinary shares will be purchased by exercising warrants	700,000
Net proceeds from share issuance		$ 9,600
Warrant to purchase ordinary share	$ 0.5
Price of shares issued under private placement	$ 8
IPO [Member] | Warrant [Member]
General [Line Items]
Number of warrants issued	1,400,000		4,500
Number of ordinary shares will be purchased by exercising warrants	700,000		2,250

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2021
Computer equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Computer equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Office furniture [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Laboratory equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Laboratory equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Significant Accounting Policies [Line Items]
Severance payment expenses		$ 137	$ 125
Severance expenses		$ 142
Number of antidilutive securities excluded from computation of earnings per share		6,517,102	7,218,966
Amgen Inc [Member]
Significant Accounting Policies [Line Items]
Non-refundable and non-creditable initial technology access fee payment, including payment for the first year of preclinical services	$ 725
Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services				$ 225
Right to use intellectual property				$ 500

OPERATING LEASE (Details)

OPERATING LEASE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 216	$ 180

OPERATING LEASE (Details 1)

OPERATING LEASE (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating cash flows from operating leases	$ 216	$ 180

OPERATING LEASES (Details 2)

OPERATING LEASES (Details 2) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Operating Leases
Operating lease right-of-use assets	$ 239	$ 374
Current lease liabilities	179	189
Non-current lease liabilities	123	243
Total lease liabilities	$ 302	$ 432
Weighted-average remaining lease term (in years)	1 year 6 months 10 days	2 years 6 months 10 days
Weighted-average discount rate	16.00%	16.00%

OPERATING LEASES (Details 3)

OPERATING LEASES (Details 3) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 224
2023	117
Total future minimum lease payments	341
Less: interest	(39)
Present value of operating lease liabilities	$ 302	$ 432

OPERATING LEASES (Detail Textua

OPERATING LEASES (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Operating leases cost for rental space and vehicles	$ 216	$ 180
Operating lease agreements for office and research and development space [Member]
Lessee, Lease, Description [Line Items]
Annual lease consideration	192
Value of bank guarantees provided	42
Operating lease agreements for vehicles for employees [Member]
Lessee, Lease, Description [Line Items]
Annual lease consideration	$ 36

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Patent Transfer Agreement [Member]
Commitments [Line Items]
Percentage of net revenues	3.00%
D.N.A Biomedical Solutions Ltd [Member] | Joint Venture Agreement [Member]
Commitments [Line Items]
Amount of investment in entity	$ 600
D. N. A Biomedical Solutions Ltd And Oramed Ltd [Member] | Joint Venture Agreement [Member]
Commitments [Line Items]
Percentage of ownership of entity acquired	50.00%
Government of Israel [Member]
Commitments [Line Items]
Percentage sales of products developed from projects in first three years, from commencement of revenues	3.00%
Percentage sales of products developed from projects subsequent three years	4.00%
Percentage sales of products developed from projects commencing the seventh year	5.00%
Total royalty amount payable	$ 460
Percentage of each payment received from Amgen	5.38%
Royalty amount paid	$ 79

SHARE CAPITAL (Detail Textuals)

SHARE CAPITAL (Detail Textuals)

Dec. 13, 2019USD ($)$ / sharesshares

Jun. 23, 2021USD ($)$ / sharesshares

Feb. 18, 2020shares

Jul. 31, 2021USD ($)$ / sharesshares

Mar. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)$ / sharesshares

Dec. 31, 2019USD ($)$ / sharesshares

Dec. 31, 2021₪ / shares

Dec. 31, 2021USD ($)$ / sharesshares

May 07, 2021shares

Jul. 31, 2020$ / sharesshares

Jul. 04, 2020USD ($)

Jun. 13, 2020$ / sharesshares

Stockholders Equity Note [Line Items]

Number of warrants issued

1,395,500

Number of ordinary shares will be purchased by exercising warrants

697,750

Exercise price of warrants issued | ₪ / shares

₪ 5.85

Transaction costs | $

$ 1,200,000

Stock-based compensation expenses | $

1,861,000

$ 901,000

Value of shares issued | $

[1]

Proceeds from issuance of shares through ATM programs, net of issuance costs | $

$ 21,805,000

$ 3,187,000

Number of options exercised

177,710

31,954

Exercise of options to ordinary shares | $

$ 418,000

$ 68,000

Weighted average exercise rice of options exercised | $ / shares

$ 2.37

$ 2.11

ATM Equity Program 2020 [Member]

Stockholders Equity Note [Line Items]

Adjusted exercise price under At-the-market equity program | $ / shares

$ 1.05

Several employees and service providers [Member]

Stockholders Equity Note [Line Items]

Number of options exercised

177,711

Private Placement [Member] | Accredited investors, including certain board members and their affiliates [Member]

Stockholders Equity Note [Line Items]

Number of warrants issued

2,855,095

Number of ordinary shares will be purchased by exercising warrants

2,855,095

Exercise price of warrants issued | $ / shares

$ 2.96

Term of warrants issued

3 years

Number of shares issued under private placement

5,710,153

Proceeds from private placement | $

$ 13,500,000

Price of shares issued under private placement | $ / shares

$ 2.37

Private Placement [Member] | D.N.A Biomedical Solutions Ltd [Member]

Stockholders Equity Note [Line Items]

Number of ordinary shares will be purchased by exercising warrants

168,776

Term of warrants issued

3 years

Number of shares issued under private placement

337,553

Proceeds from private placement | $

$ 800

Private Placement [Member] | Chairman of the board and DNA [Member] | Series B Preferred Stock [Member]

Stockholders Equity Note [Line Items]

Number of ordinary shares will be purchased by exercising warrants

687,960

Exercise price of warrants issued | $ / shares

$ 6.99

Private Placement [Member] | Chairman of the board and DNA [Member] | Series A Preferred Stock [Member]

Stockholders Equity Note [Line Items]

Number of ordinary shares will be purchased by exercising warrants

340,210

Exercise price of warrants issued | $ / shares

$ 3.69

Placement Agency agreement with GP Numenkari Inc [Member] | D.N.A Biomedical Solutions Ltd [Member]

Stockholders Equity Note [Line Items]

Cash fees in percentage of total proceeds paid by subscribers invested through the Broker

10.00%

Ordinary shares [Member]

Stockholders Equity Note [Line Items]

Voting rights of ordinary share

one vote

Number of options exercised

177,711

31,954

Exercise of options to ordinary shares | $

$ 0

$ 0

Ordinary shares [Member] | ATM Equity Program 2020 [Member]

Stockholders Equity Note [Line Items]

Value of shares issued | $

$ 13,900,000

Effect of down round trigger amount | $

1,042,000,000

Proceeds from issuance of shares through ATM programs, net of issuance costs | $

$ 3,500,000

Weighted average price of share issued | $ / shares

$ 3.99

$ 1.27

Net proceeds from share issuance | $

$ 9,900,000

$ 3,200,000

Number of shares issued

2,546,265

2,802,731

Ordinary shares [Member] | ATM Equity Program 2021 [Member]

Stockholders Equity Note [Line Items]

Weighted average price of share issued | $ / shares

$ 6.74

Net proceeds from share issuance | $

$ 12,100,000

Number of shares issued

1,840,463

5,000,000

Ordinary shares [Member] | Several employees and service providers [Member]

Stockholders Equity Note [Line Items]

Number of shares issued on options exercised

177,711

Weighted average exercise rice of options exercised | $ / shares

$ 2.54

Ordinary shares [Member] | IPO [Member]

Stockholders Equity Note [Line Items]

Number of ordinary shares will be purchased by exercising warrants

700,000

Price of shares issued under private placement | $ / shares

$ 8

Net proceeds from share issuance | $

$ 9,600,000

Number of shares issued

1,400,000

Ordinary shares [Member] | Private Placement [Member] | Chairman of the board and DNA [Member]

Stockholders Equity Note [Line Items]

Number of ordinary shares will be purchased by exercising warrants

3,172,800

Warrant [Member] | IPO [Member]

Stockholders Equity Note [Line Items]

Number of warrants issued

4,500

1,400,000

Number of ordinary shares will be purchased by exercising warrants

2,250

700,000

Exercise price of warrants issued | $ / shares

$ 5.85

$ 8.4

Term of warrants issued

5 years

Threshold limit of period for reduction in exercise price

2 years

Threshold limit of reduction in exercise price | $ / shares

$ 8

Reduced exercise price | $ / shares

$ 5.85

Proceeds from exercise of warrants | $

$ 13,000

Warrant [Member] | Private Placement [Member] | Chairman of the board and DNA [Member]

Stockholders Equity Note [Line Items]

Number of warrants issued

3,300,645

340,210

687,960

Exercise price of warrants issued | $ / shares

$ 1.05

Proceeds from exercise of warrants | $

$ 3,145,000

Broker Warrants Type 1 [Member] | Placement Agency agreement with GP Numenkari Inc [Member] | D.N.A Biomedical Solutions Ltd [Member]

Stockholders Equity Note [Line Items]

Number of warrants issued

184,515

Exercise price of warrants issued | $ / shares

$ 2.37

Term of warrants issued

3 years

Shares granted in percentage

10.00%

Broker Warrants Type 2 [Member] | Placement Agency agreement with GP Numenkari Inc [Member] | D.N.A Biomedical Solutions Ltd [Member]

Stockholders Equity Note [Line Items]

Number of warrants issued

92,257

Exercise price of warrants issued | $ / shares

$ 2.96

Term of warrants issued

3 years

Shares granted in percentage

5.00%

Broker Warrants [Member] | Placement Agency agreement with GP Numenkari Inc [Member] | D.N.A Biomedical Solutions Ltd [Member]

Stockholders Equity Note [Line Items]

Stock-based compensation expenses | $

$ 205,000

[1]

Represents an amount less than one thousand US dollars

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 1.24	$ 1.06
Expected volatility	68.00%	66.35%
Risk-free interest rate	1.11%	0.16%
Expected life - in years	6 years 1 month 6 days	2 years 9 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 3.61	$ 2.14
Expected volatility	71.00%	71.00%
Risk-free interest rate	0.94%	0.58%
Expected life - in years	5 years 9 months 18 days	6 years 1 month 6 days

SHARE-BASED COMPENSATION (Det_2

SHARE-BASED COMPENSATION (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of options
Outstanding at beginning of year	2,570,109	2,847,600
Granted	1,975,586	570,362
Exercised	(177,710)	(31,954)
Forfeited	(16,660)	(589,793)
Expired	(34,466)	(226,106)
Outstanding at end of year	4,316,859	2,570,109
Exercisable at end of year	2,068,067	1,791,687
Weighted Average exercise price
Outstanding at beginning of year	$ 4.85	$ 4.74
Granted	1.95	1.98
Exercised	2.37	2.11
Forfeited	2.37	2.7
Expired	4	2.68
Outstanding at end of year	3.63	4.85
Exercisable at end of year	$ 5.39	$ 5.49

SHARE-BASED COMPENSATION (Det_3

SHARE-BASED COMPENSATION (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 3.63	$ 4.85	$ 4.74
Number of options outstanding at end of year	4,316,859	2,570,109	2,847,600
Number of options exercisable at end of year	2,068,067	1,791,687
Exercise Price Per Share - Zero
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 0
Number of options outstanding at end of year	4,680
Options outstanding, Weighted Average Remaining contractual Life	9 months 10 days
Number of options exercisable at end of year	4,680
Options exercisable, Weighted Average Remaining contractual Life	9 months 10 days
Exercise Price Per Share - 1.06
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 1.06
Number of options outstanding at end of year	14,760
Options outstanding, Weighted Average Remaining contractual Life	3 years 10 months 6 days
Number of options exercisable at end of year	14,760
Options exercisable, Weighted Average Remaining contractual Life	3 years 10 months 6 days
Exercise Price Per Share - 1.24
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 1.24
Number of options outstanding at end of year	1,314,218
Options outstanding, Weighted Average Remaining contractual Life	9 years 7 days
Number of options exercisable at end of year	0
Exercise Price Per Share - 2.14
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 2.14
Number of options outstanding at end of year	422,300
Options outstanding, Weighted Average Remaining contractual Life	8 years 3 months 3 days
Number of options exercisable at end of year	184,756
Options exercisable, Weighted Average Remaining contractual Life	8 years 3 months 3 days
Exercise Price Per Share - 2.53
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 2.53
Number of options outstanding at end of year	33,638
Options outstanding, Weighted Average Remaining contractual Life	7 years 10 months 20 days
Number of options exercisable at end of year	28,031
Options exercisable, Weighted Average Remaining contractual Life	7 years 10 months 20 days
Exercise Price Per Share - 3.15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 3.15
Number of options outstanding at end of year	345,000
Options outstanding, Weighted Average Remaining contractual Life	9 years 3 months 18 days
Number of options exercisable at end of year	0
Exercise Price Per Share - 3.61
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 3.61
Number of options outstanding at end of year	316,368
Options outstanding, Weighted Average Remaining contractual Life	9 years 3 months 7 days
Number of options exercisable at end of year	5,561
Options exercisable, Weighted Average Remaining contractual Life	9 years 3 months 7 days
Exercise Price Per Share - 3.68
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 3.68
Number of options outstanding at end of year	185,640
Options outstanding, Weighted Average Remaining contractual Life	3 months 25 days
Number of options exercisable at end of year	185,640
Options exercisable, Weighted Average Remaining contractual Life	3 months 25 days
Exercise Price Per Share - 3.97
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 3.97
Number of options outstanding at end of year	287,565
Options outstanding, Weighted Average Remaining contractual Life	7 years 18 days
Number of options exercisable at end of year	251,949
Options exercisable, Weighted Average Remaining contractual Life	7 years 18 days
Exercise Price Per Share - 6.31
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 6.31
Number of options outstanding at end of year	1,245,400
Options outstanding, Weighted Average Remaining contractual Life	4 years 29 days
Number of options exercisable at end of year	1,245,400
Options exercisable, Weighted Average Remaining contractual Life	4 years 29 days
Exercise Price Per Share - 7.54
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share	$ 7.54
Number of options outstanding at end of year	147,290
Options outstanding, Weighted Average Remaining contractual Life	1 year 3 months 3 days
Number of options exercisable at end of year	147,290
Options exercisable, Weighted Average Remaining contractual Life	1 year 3 months 3 days

SHARE-BASED COMPENSATION (Det_4

SHARE-BASED COMPENSATION (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 1,861	$ 901
Cost of revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	102	51
Research and development expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	661	514
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 1,098	$ 336

SHARE-BASED COMPENSATION (Det_5

SHARE-BASED COMPENSATION (Detail Textuals)

Apr. 07, 2021USD ($)$ / sharesshares

Jan. 04, 2021USD ($)$ / sharesshares

Aug. 23, 2021USD ($)$ / sharesshares

Apr. 21, 2021USD ($)$ / sharesshares

Nov. 30, 2020USD ($)$ / sharesshares

Apr. 30, 2020USD ($)shares

Apr. 20, 2020USD ($)$ / sharesshares

Mar. 16, 2020USD ($)$ / sharesshares

Dec. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)$ / sharesshares

Dec. 31, 2021₪ / shares

Dec. 31, 2021USD ($)shares

Dec. 31, 2020₪ / shares

Jul. 02, 2018₪ / sharesshares

Mar. 17, 2013₪ / shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Ordinary share, par value | ₪ / shares

₪ 0.0000769

₪ 0.0000769

Ordinary shares available for future grant

289,638

Number of additional ordinary shares authorized

1,440,220

Number of options to purchase ordinary shares

1,975,586

570,362

Exercise price of options granted | $ / shares

$ 1.95

$ 1.98

Aggregate intrinsic value of outstanding options | $

$ 2,378,000

Aggregate intrinsic value of exercisable options | $

$ 146,000

Stock-based compensation expenses | $

$ 1,861,000

$ 901,000

Investor relations services agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted Share Units vested

21,000

Investor relations services agreement | Restricted Stock Units (RSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Fair value of options at the date of grant | $

$ 53

Certain employees

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase ordinary shares

213,000

201,600

Exercise price of options granted | $ / shares

$ 3.61

$ 2.14

Vestion period

4 years

4 years

Fair value of options at the date of grant | $

$ 646,000

$ 590

Certain employees | Vest on the first anniversary of the date of grant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

25.00%

25.00%

Certain employees | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

75.00%

75.00%

Service Provider

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase ordinary shares

70,000

7,500

Exercise price of options granted | $ / shares

$ 3.61

$ 2.14

Vestion period

4 years

4 years

Fair value of options at the date of grant | $

$ 646,000

$ 590

Service Provider | Vest on the first anniversary of the date of grant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

25.00%

25.00%

Service Provider | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

75.00%

75.00%

Executive Officer

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase ordinary shares

345,000

250,000

Exercise price of options granted | $ / shares

$ 3.15

$ 2.14

Vestion period

4 years

4 years

Fair value of options at the date of grant | $

$ 1,140,000

$ 590

Executive Officer | Vest on the first anniversary of the date of grant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

25.00%

25.00%

Executive Officer | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

75.00%

75.00%

Former CEO

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase ordinary shares

31,502

Exercise price of options granted | $ / shares

$ 1.98

Vestion period

4 years

Fair value of options at the date of grant | $

$ 37

Former CEO | Vest on the first anniversary of the date of grant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

25.00%

Former CEO | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

75.00%

Consultant | Investor relations services agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Monthly fee | $

$ 5

Consultant | Investor relations services agreement | Restricted Stock Units (RSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted Share Units granted

28,000

Consultant | Amendment to business development services agreement

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase ordinary shares

79,760

Exercise price of options granted | $ / shares

$ 1.06

Fair value of options at the date of grant | $

$ 35

Monthly fee | $

$ 5

Consultant | Shares vested on the signing date | Investor relations services agreement | Restricted Stock Units (RSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted Share Units vested

7,000

Consultant | Vest in three equal installments until January 8, 2021 | Investor relations services agreement | Restricted Stock Units (RSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted Share Units vested

21,000

Chief Executive Officer

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase ordinary shares

1,314,218

Exercise price of options granted | $ / shares

$ 1.24

Fair value of options at the date of grant | $

$ 1,320,000

Chief Executive Officer | Vest on the first anniversary of the date of grant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

25.00%

Chief Executive Officer | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

75.00%

Non-executive director

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase ordinary shares

33,368

Exercise price of options granted | $ / shares

$ 3.61

Vestion period

3 years

Fair value of options at the date of grant | $

$ 104,000

Non-executive director | Vest over twelve equal quarterly instalments starting on January 1, 2022

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase ordinary shares

752,899

Exercise price of options granted | $ / shares

$ 2.815

Vestion period

3 years

Fair value of options at the date of grant | $

$ 195,000

Non-executive director | Vest over four equal quarterly instalments starting on January 1, 2022

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options to purchase ordinary shares

250,964

Exercise price of options granted | $ / shares

$ 2.815

Vestion period

1 year

Fair value of options at the date of grant | $

$ 65,000

2013 Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Ordinary share, par value | ₪ / shares

₪ 0.000769

2018 Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Ordinary share, par value | ₪ / shares

₪ 0.0000769

Number of ordinary shares authorized

1,371,398

INCOME TAX (Details)

INCOME TAX (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Loss (income) before income taxes	$ 12,246	$ 11,196
Entera Bio Ltd
Operating Loss Carryforwards [Line Items]
Loss (income) before income taxes	12,362	11,283
Entera Bio Inc
Operating Loss Carryforwards [Line Items]
Loss (income) before income taxes	$ (116)	$ (87)

INCOME TAX (Details 1)

INCOME TAX (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current:
Total current income tax	$ 158	$ 20
Deferred:
Total deferred income tax	217	0
Total tax on income	(59)	20
Subsidiary
Current:
Total current income tax	158	20
Deferred:
Total deferred income tax	$ (217)	$ 0

INCOME TAX (Details 2)

INCOME TAX (Details 2) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carry forward	$ 12,895	$ 10,176
Research and development	1,319	1,316
Share-based compensation	876	688
Other	152	240
Net deferred tax assets before valuation allowance	15,242	12,420
valuation allowance	(15,025)	(12,420)	$ (9,718)
Net deferred tax assets	$ 217	$ 0

INCOME TAX (Details 3)

INCOME TAX (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Opening balance	$ 12,420	$ 9,718
Additions	2,605	2,702
Closing balance	$ 15,025	$ 12,420

INCOME TAX (Detail Textuals)

INCOME TAX (Detail Textuals) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Carryforward losses	$ 56.1	$ 44.2
Israeli tax rate [Member]
Operating Loss Carryforwards [Line Items]
Income tax rate	23.00%
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Income tax rate	29.00%

SUPPLEMENTARY FINANCIAL STATE_3

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounts payable - other:
Employees and employees related	$ 147	$ 144
Income tax	134	0
Provision for vacation	308	263
Accrued expenses	2,212	923
Accrued Liabilities and Other Liabilities, Total	$ 2,801	$ 1,330

REVENUE FROM COLLABORATION AN_2

REVENUE FROM COLLABORATION AND LICENSE AGREEMENT (Detail Textuals) - USD ($) $ in Thousands	Dec. 10, 2018	Jan. 31, 2019	Dec. 31, 2018	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues					$ 571	$ 365
Amgen Inc [Member]
Disaggregation of Revenue [Line Items]
Milestone payments	$ 270,000
Amount to be paid for preclinical services	$ 450				450
Non-refundable and non-creditable initial technology access fee payment		$ 725
Selling price of preclinical R&D services		225
Right to use intellectual property		$ 500
Research and development service expense				$ 450
Contract liabilities					15	158
Amgen Inc [Member] | Intellectual Property [Member]
Disaggregation of Revenue [Line Items]
Revenues			$ 500
Service [Member] | Amgen Inc [Member]
Disaggregation of Revenue [Line Items]
Revenues					$ 502	$ 365